• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 15th December 2015

Just Published: Systematic Review of PRO Use in Paediatric Populations with Vaccine-Preventable Infectious Diseases

This paper reports the results of a systematic review of the use and quality of Patient Reported Outcome (PRO) measures in paediatric populations with vaccine-preventable infectious diseases in developed countries. The results of a systematic review on the use of…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

This paper reports the results of a systematic review of the use and quality of Patient Reported Outcome (PRO) measures in paediatric populations with vaccine-preventable infectious diseases in developed countries.

The results of a systematic review on the use of patient reported outcomes (PROs) in paediatric populations with infectious diseases were recently published in Value in Health. 

The Patient-Reported Outcomes in Children with Infectious Diseases (PROCHID) study was performed in 2013 – 2014 by a team of researchers from OHE in collaboration with members of Sanofi Pasteur MSD’s HEOR team and focused on the use of PRO measures in any of 17 vaccine-preventable infectious diseases. 

To ensure feasibility, the review was restricted to the use of PROs in regions and countries where PROs are widely used and can contribute to decision making on the value of treatments (Europe, North America, Australia and New Zealand). 

Searches were performed in the Scopus and Psychlit electronic databases in conjunction with manual searching of reference lists in relevant articles.

Although a large number of titles and abstracts were reviewed, only a small number of full-text articles (n=17) were included for data extraction, indicating the dearth of research in this area. No PRO studies in paediatric populations were identified for 9 of the 17 conditions studied. 

PRO instruments used in the studies identified included a range of generic and disease-specific measures. The majority of the instruments used in the studies identified were of satisfactory or good quality in terms of their psychometric performance. 

In some instances, questionnaires for adults were used which might be unsuitable for younger populations, and there were other cases where proxy perceptions of children’s health were obtained when it would have been possible to obtain children’s perceptions directly. 

Only one questionnaire was identified which had been specifically designed for children with one of the diseases included, though it was still in the development stage.

The authors conclude that the lack of studies and disease-specific PRO instruments in paediatric populations with vaccine-preventable infectious diseases is a serious obstacle to the comprehensive assessment of the impact of those conditions or the benefits of their prevention and treatment. 

Access the full paper here.

This paper is one of two to be published in Value in Health stemming from the PROCHID study. The other is a review of the derivation and use of utility weights in paediatric populations with any of the same 17 vaccine-preventable diseases and has also been accepted for publication. 

In recent years, members of OHE have contributed to several studies involving the development and/or use of PRO measures in younger populations, including:

  • development [open access] and validation [open access] of the EQ-5D-Y, the version of EQ-5D for children
  • development and validation of a condition-specific measure of HRQOL for use in short stature children [open access]
  • development and use of a widely used, generic measure of children’s HRQOL, the KIDSCREEN [open access]
  • exploration of socioeconomic inequalities in HRQOL in children and adolescents across Europe.
 
For more information on OHE’s research in this area, please contact Mike Herdman or Nancy Devlin.
  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!